Online citations, reference lists, and bibliographies.
← Back to Search

PREPARATION OF PROTEIN-LOADED PLGA-PVP BLEND NANOPARTICLES BY NANOPRECIPITATION METHOD: ENTRAPMENT, INITIAL BURST AND DRUG RELEASE KINETIC STUDIES

Shahryar Shakeri, R. Roghanian, G. Emtiazi, C. Errico, E. Chiellini, F. Chiellini
Published 2015 · Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
Objective(s):Despite of wide range applications of polymeric nanoparticles in protein delivery, there are some problems for the field of protein entrapment, initial burst and controlled release profile. Materials and Methods: In this study, we investigated the influence of some changes in PLGA nanoparticles formulation to improve the initial and controlled release profile. Selected parameters were: pluronic F127, polysorbate 80 as surfactant, pH of inner aqueous phase, L/G ratio of PLGA polymer, volume of inner aqueous phase and addition of polyvinylpyrrolidone as an excipient. FITC-HSA was used as a model hydrophilic drug. The nanoparticles were prepared by nanoprecipitation. Results:  Initial release of FITC-HSA from PLGA-tween 80 nanoparticles (opt-4, 61%) was faster than control (PLGA-pluronic) after 2.30 h of incubation. Results showed that decrease in pH of inner aqueous phase to pI of protein can decrease IBR but the release profile of protein is the same as control. Release profile with three phases including a) initial burst b) plateau and c) final release phase was observed when we changed volume of inner aqueous phase and L/G ratio in formulation. Co-entrapment of HSA with PVP and pluronic reduced the IBR and controlled release profile in opt-19. Encapsulation efficiency was more than 97% and nanoparticles size and zeta potentials were mono-modal and -18.99 mV, respectively. Conclusion:  In this research, we optimized a process for preparation of PLGA-PVP-pluronic nanoparticles of diameter less than 300 nm using nanoprecipitation method. This formulation showed a decreased initial burst and long lasting controlled release profile for FITC-HSA as a model drug for proteins.
This paper references
10.1016/S0169-409X(02)00228-4
Biodegradable nanoparticles for drug and gene delivery to cells and tissue.
J. Panyam (2003)
Pan yam J. P olym er-s urfa ctan t na nopa rtic les for sustained release of water-soluble drugs
M D Chavanpatil (2007)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
10.1016/J.JCONREL.2004.06.018
Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation.
D. Le Garrec (2004)
10.1016/j.biomaterials.2008.12.013
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
J. M. Chan (2009)
10.1163/1568562041753098
Design and characterisation of new nanoparticulate polymer blends for drug delivery
N. Csaba (2004)
10.2174/0929867043455909
Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.
S. Feng (2004)
10.1089/PHO.2007.2089
Characterization of biodegradable poly(D,L-lactide-co-glycolide) nanoparticles loaded with bacteriochlorophyll-a for photodynamic therapy.
A. Gomes (2007)
10.1038/nbt798
Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting
H. Kamada (2003)
10.2174/156720107780362339
Recent advances in protein and peptide drug delivery systems.
Dhirendra Kumar Malik (2007)
10.1016/J.JCONREL.2003.09.014
Polyvinylpyrrolidone-drug conjugate: synthesis and release mechanism.
A. D'souza (2004)
10.1021/BM049577P
PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery.
N. Csaba (2005)
10.1517/17425247.2.1.29
Commercial challenges of protein drug delivery
L. Brown (2005)
10.1016/S0378-5173(99)00152-0
Instability, stabilization, and formulation of liquid protein pharmaceuticals.
W. Wang (1999)
10.1126/SCIENCE.1702556
Three-dimensional structures of acidic and basic fibroblast growth factors.
X. Zhu (1991)
10.1021/mp800137z
Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited.
Peisheng Xu (2009)
10.1021/mp1001262
Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors.
I. d'Angelo (2010)
10.1016/J.BIOMATERIALS.2006.06.029
Ultra-low sized cross-linked polyvinylpyrrolidone nanoparticles as non-viral vectors for in vivo gene delivery.
A. Saxena (2006)
10.1201/b15645-8
Nanoparticles of biodegradable polymers for cancer treatment.
S. Feng (2008)
10.1002/JPS.20961
Polymer-surfactant nanoparticles for sustained release of water-soluble drugs.
M. Chavanpatil (2007)
10.1517/17425240903394520
Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors
V. Balasubramanian (2010)
10.2217/17435889.3.3.367
Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications.
F. Chiellini (2008)
10.1152/physrev.1999.79.4.1283
Mechanism of action and in vivo role of platelet-derived growth factor.
C. Heldin (1999)
10.1017/S0266462300014045
Novel approaches to controlled-release antigen delivery.
S. Cohen (1994)
Polymer - surfactan t nanopart ic les for sustained release of water - soluble drugs
Chavanpatil (2007)
10.1615/CRITREVTHERDRUGCARRIERSYST.V21.I5.20
PLGA nanoparticles in drug delivery: the state of the art.
I. Bala (2004)
10.1016/S0168-3659(00)00249-2
Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice.
S. Tsunoda (2000)
10.1016/S0939-6411(98)00011-3
Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants.
D. Blanco (1998)
10.1023/A:1016039330870
Polyvinyl Derivatives as Novel Interactive Polymers for Controlled Gene Delivery to Muscle
R. Mumper (2004)
PVP: a critical review of the kinetics and toxicology of polyvi nylp yrrolidone (Povi done). M ichi gan
B V Roninson (1990)
N-vinylpyrrolidone)-block-poly(D,Llactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation
Le Garrec (2004)
10.1007/S00396-009-2131-Z
Protein-loaded PLGA–PEO blend nanoparticles: encapsulation, release and degradation characteristics
M. J. Santander-Ortega (2010)
10.1023/A:1018908421434
Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release
H. Yoo (2004)
10.1002/MABI.200500146
Intrinsic adhesion properties of poly(vinyl pyrrolidone) to pharmaceutical materials: humidity effect.
J. Lee (2005)
10.1208/s12249-009-9330-2
Surfactant-free Formulation of Poly(Lactic/Glycolic) Acid Nanoparticles Encapsulating Functional Polypeptide: A Technical Note
Y. Wang (2009)
10.1517/17425240802680169
Current approaches to stabilising and analysing proteins during microencapsulation in PLGA
C. F. van der Walle (2009)
10.1016/S0928-0987(03)00019-8
Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha.
A. Sánchez (2003)
10.2174/157339510790231798
Microencapsulation of Vaccine Antigens and Adjuvants for Mucosal Targeting
Thejani E. Rajapaksa and David D. Lo (2010)
10.1517/17425240802680169
Current approaches to stabilising and analysing proteins during microencapsulation in PLGA.
C. F. van der Walle (2009)
Preparation of protein-loaded PLGA-PVP blend nanoparticles by nanoprecipitation method: Entrapment, Initial burst and drug release kinetic studies
Y Yamamoto (2004)
10.2174/187152006776930864
Promotion of optimized protein therapy by bioconjugation as a polymeric DDS.
Y. Abe (2006)
10.1080/02652040600946886
Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin
C. Lecároz (2006)
10.3109/02652049009021842
Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties.
R. Jalil (1990)
10.1016/S0021-9797(02)00099-1
Cross-linked polyvinylpyrrolidone nanoparticles: a potential carrier for hydrophilic drugs.
D. J. Bharali (2003)
10.1021/LA020376L
Inhibition of Protein Adsorption onto Silica by Polyvinylpyrrolidone
S. Robinson (2002)
10.1007/S11167-005-0210-6
Binding of protein to polystyrene particles in the presence of polyvinylpyrrolidone in the surface layer
A. Y. Men’shikova (2004)
Binding of protein to
A Y Menaposshikova
10.1016/S0168-3659(98)00006-6
The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method.
A. Coombes (1998)
10.1093/JAC/DKI455
Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
E. Charvalos (2006)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar